Warning letter · FDA Warning Letters

Amazon.com, Inc.: FDA Warning Letter 631751 (Oct 28, 2022)

Agency action: Oct 28, 2022Record ID: fda_warning_-532332004084b861
View official source ↗

What happened

Original notice title

Amazon.com, Inc. MARCS-CMS 631751, October 28, 2022

From the archived source record

a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article's labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The respective labeling for “Artri Ajo King,” “Artri King Reforzado con Ortiga y Omega 3,” and “Ortiga Mas Ajo Rey” does not declare that the products contain the drug ingredient diclofenac. As discussed earlier, diclofenac (and other NSAIDs) can lead to adverse cardiovascular events, such as heart attack and stroke, or serious gastrointestinal damage, including bleeding, ulceration, and fatal tears of the stomach and intestines, or liver toxicity including liver failure that can cause the need for a liver transplant or death. The failure to disclose this ingredient in the products’ labeling renders “Artri Ajo King,” “Artri King Reforzado con Ortiga y Omega 3,” and “Ortiga Mas Ajo Rey” misbranded under section 502(a) of the FD&C Act. The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Conclusion The violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. This letter notifies you of our concerns and provides you an opportunity to address them.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
38f8e4b3a6bc

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Artri Ajo King; Artri King Reforzado con Ortiga y Omega 3; Ortiga Mas Ajo Rey; Artri Ajo King Reforzado con Ortiga y Omega 3; Dolor de Artritis; Reumas
Company
Amazon.com, Inc.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.